Publications
Salim SK, Shaikh MV, Wei J, Maich WT, Anand A, Tang OY, Subapanditha MK, Alizada Z, Suk Y, Singh M, Zhai K, Khanna A, Brakel B, Dimitrov V, Tabunshchyk Z, Chan K, Brown KR, Vora P, O'Rourke DM, Binder ZA, Venugopal C, Moffat J, Singh SK Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma. , Int J Cancer, 159(6): 2026
Linkowski L, Messing I, Berger M, Hollawell C, Friedes C, Alexander D, Wang X, Desai AS, Phillips RE, O'Rourke DM, Amankulor NM, Jackson C, Hubbeling H, Kurtz G, Bagley SJ, Bradley JD, Mohan S, Alonso-Basanta M, Lebow ES Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series. , Int J Radiat Oncol Biol Phys. : 2026
Liu S, Rook AH, Huang AC, Maity A, Qin Z, Chen Y, Song D, Deng Y, Huang Z, Karakousis GC, Mitchell TC, Amaravadi RK, Schuchter LM, Binder ZA, O'Rourke DM, Herlyn M, Guo W, Xu X Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells. , Cancer Immunol Res.: 2026
Li EJ, Kraya A, Costa-Pinheiro P, Scheuermann J, Young AJ, Schubert E, Aboian M, Doot R, Ware JB, Pantel AR, Binder ZA, Storm PB, Resnick AC, Amankulor NM, O'Rourke DM, Desai A, Nasrallah MP, Brem S, Bagley SJ, Mankoff D, Nabavizadeh A Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma. , JK Nuc Med, 67(6): 2026
Akbari H, Mohan S, Liu F, Jiang C, Fathi Kazerooni A, Berger M, Rathore S, Bilello M, Sako C, Garcia J, Brem S, Bakas S, Mamourian E, Pepin A, James P, Dorsey J, Singh A, Parker D, Verma R, Cao Q, Bagley SJ, Desai A, O'Rourke DM, Shinohara RT, Nasrallah MP, Teo BK, Kurtz G, Shukla G, Alonso-Basanta M, Lustig RA, Davatzikos C Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study. , Nat Commun., 17(1): 2026
Wei S, Deng Y, Lee J, Lan H, Yang Z, Labrie M, Betts CB, Duan H, Tate B, Pucilowska J, Frederick D, Lawless AR, Sharova T, Yang Y, Hu W, Beasley GM, Schuchter LM, Wang X, Xu W, Yong G, Vandenberg MEG, Torigian DA, Sivagnanam S, Du K, Sugarman E, McGettigan S, Zheng C, Al-Rohil RN, Selim MA, Datto MB, López GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O'Rourke DM, Brem S, O'Malley BW, Demirkan G, Yu S, Lu Y, Camp T, Patterson JA, Wei Z, Corless C, Gabrilovich DI, Mou Y, Flaherty KT, Coussens LM, Boland G, Herlyn M, Mills G, Liu L, Zhang G A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. , Cell Rep Med, 7(4): 2026
Friedes C, Berger M, Linkowski L, Hollawell C, Hubbeling H, Alexander D, Kurtz G, Lustig RA, Dorsey JF, Desai AS, Phillips RE, Brem S, Davatzikos C, Nasrallah M, O'Rourke DM, Jackson C, Amankulor NM, Alonso-Basanta M, Mohan S, Bagley SJ, Lebow ES Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study. , J Neurooncol: 2026
Cordell EC, Mansour M, Pantel AR, Schubert E, Nabavizadeh A, Mohan S, Maloney E, Prior T, Angeloni N, Blessing C, Frangos S, Coghlan L, Wileyto EP, O'Rourke DM, Brem S, Desai AS, Bagley SJ A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma. , Neurooncol Adv. : 2026
Freeburg NF, Chafamo D, Konanur Gopikrishna G, Murphy RM, Peng JJ, Parthasarathy S, Dumont S, Estrada EG, Logun MT, Sun Y, Wang X, Grover P, Rodriguez JL, Zhang DL, Park K, Fu Y, Ben Hamouda N, Hernandez-Verdin I, Lamrani L, Hicks KA, Cooper NA, Ekwegbara C, Bawden EG, Waterfall JJ, Fuentealba J, Alcantara M, Seykora JT, Prouty SM, Barrett D, Banerjee E, Cox A, Assenmacher CA, Macia C, Yin M, Carpenter EL, Ming GL, Sautès-Fridman C, Fridman WH, Tartour E, Wherry EJ, Amigorena S, Fraietta JA, Nasrallah MP, Song H, Miller TE, Bagley SJ, O'Rourke DM, Binder ZA, Alanio C, Silverbush D. The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. , Cell: 2026
Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: a phase 1 trial , Nat Med: 2025
